Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?

Addiction

Volumn 108, Issue 6, 2013, Pages 1070-1081

  De Vos, Anneke S ^a   Van der Helm, Jannie J ^b   Matser, Amy ^a,b   Prins, Maria ^b,c   Kretzschmar, Mirjam E E ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Demography; Harm reduction; HCV; HIV; Injecting drug use; Theoretical models

Indexed keywords

ADULT; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG ABUSE; HARM REDUCTION; HEPATITIS C, CHRONIC; HIGH RISK BEHAVIOR; HIV INFECTIONS; HUMAN; INCIDENCE; MIDDLE AGED; NETHERLANDS; PREVENTION AND CONTROL; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; YOUNG ADULT; ARTICLE; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; STATISTICS;

ADULT; COHORT STUDIES; HARM REDUCTION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INCIDENCE; MIDDLE AGED; NEEDLE SHARING; NETHERLANDS; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84877642620     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12125     Document Type: Article

References (43)

1. Rhodes, T., Hedrich, D., editors. Monographs 10. Harm Reduction: Evidence, Impacts and Challenges. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction; 2010. ISBN 978-92-9168-419-9. doi: 10.2810/29497.
2. Amundsen E. J. Measuring effectiveness of needle and syringe exchange programmes for prevention of HIV among injecting drug users. Addiction 2006; 101: 911-912.
3. Wodak A., Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse 2006; 41: 777-813.
4. Wodak A. Health exchange and prevention of HIV: the evidence for effectiveness is beyond dispute. Addiction 2007; 102: 161-163.
5. Palmateer N., Kimber J., Hickman M., Hutchinson S., Rhodes T., Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010; 105: 844-859.
6. Turner K. M., Hutchinson S., Vickerman P., Hope V., Craine N., Palmateer N. etal. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106: 1978-1988.
7. Hagan H., Pouget E. R., Des Jarlais D. C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011; 204: 74-83.
8. Van Den Berg C., Smit C., Van Brussel G., Coutinho R., Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454-1462.
9. Hutchinson S. J., Bird S. M., Taylor A., Goldberg D. J. Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: implications for prevention. Int J Drug Policy 2006; 17: 211-221.
10. Israëls H., Mooij A., editors. Crisis and new life (after 1980). In: Aan De Achtergracht Honderd Jaar GG&GD [At the Achtergracht One Hundred Years of GG&GD]. Amsterdam: Bert Bakker; 2001, p. 174-204.
11. van den Berg C. H., Smit C., Bakker M., Geskus R. B., Berkhout B., Jurriaans S. etal. Major decline of hepatitis C virus rate over two decades in a cohort of drug users. Eur J Epidemiol 2007; 22: 183-193.
12. van Ameijden E. J., Coutinho R. A. Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions. J Epidemiol Community Health 2001; 55: 356-363.
13. de Vos A. S., van der Helm J. J., Prins M., Kretzschmar M. E. Determinants of persistent spread of HIV in HCV-infected populations of injecting drug users. Epidemics 2012; 4: 57-67.
14. Termorshuizen F., Krol A., Prins M., van Ameijden E. J. Long-term outcome of chronic drug use: the Amsterdam Cohort Study among drug users. Am J Epidemiol 2005; 161: 271-279.
15. van den Berg C. H., Grady B. P., Schinkel J., van de Laar T., Molenkamp R., van Houdt R. etal. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS ONE 2011; 6: e27555.
16. Matser A., Urbanus A., Geskus R., Kretzschmar M., Xiridou M., Buster M. etal. The effect of hepatitis C treatment and HIV coinfection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 2012; 107: 614-623.
17. Bindels P. J., Reijneveld S. A., Mulder-Folkerts D. K., Coutinho R. A., van den Hoek A. A. Impact of AIDS on premature mortality in Amsterdam, 1982-1992. AIDS 1994; 8: 233-237.
18. van Haastrecht H. J., Bindels P. J., van den Hoek A. A., Coutinho R. A. Estimating the size of the HIV epidemic among injecting drug users in Amsterdam. Eur J Epidemiol 1997; 13: 261-265.
19. Pybus O. G., Cochrane A., Holmes E. C., Simmonds P. The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol 2005; 5: 131-139.
20. R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2011. ISBN 3-900051-07-0. Available at: http://www.R-project.org/ (accessed 21 February 2013).
21. Smit C., Geskus R., Walker S., Sabin C., Coutinho R., Porter K. etal. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20: 741-749.
22. CASCADE Collaboration, Babiker A., Bhaskaran K., Darbyshire J., Pezzotti P., Porter K. etal. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 18: 1267-1274.
23. Baggaley R. F., Boily M. C., White R. G., Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006; 20: 805-812.
24. Hollingsworth T. D., Anderson R. M., Fraser C. HIV-1 transmission by stage of infection. J Infect Dis 2008; 198: 687-693.
25. Cohen M. S. Amplified transmission of HIV-1: missing link in the HIV pandemic. Trans Am Clin Climatol Assoc 2006; 117: 213-224.
26. Pilcher C. D., Joaki G., Hoffman I. F., Martinson F. E., Mapanje C., Stewart P. W. etal. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21: 1723-1730.
27. Attia S., Egger M., Müller M., Zwahlen M., Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 17: 1397-1404.
28. Micallef J. M., Kaldor J. M., Dore G. J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41.
29. Grebely J., Prins M., Hellard M., Cox A. L., Osburn W. O., Lauer G. etal. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012; 12: 408-414.
30. MacDonald M., Crofts N., Kaldor J. Transmission of hepatitis C virus: rates, routes, and cofactors. Epidemiol Rev 1996; 18: 137-148.
31. De Carli G., Puro V., Ippolito G. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 2003; 31: 22-27.
32. Yazdanpanah Y., De Carli G., Migueres B., Lot F., Campins M., Colombo C. etal. Risk factors for hepatitis C virus transmission to Health Care Workers after occupational exposure: a European case-control study. Rev Epidemiol Sante Publique 2006; 54: 1S23-131.
33. Sutton A. J., Hope V. D., Mathei C., Mravcik V., Sebakova H., Vallejo F. etal. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. J Viral Hepat 2008; 15: 809-816.
34. Garfein R. S., Vlahov D., Galai N., Doherty M. C., Nelson K. E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 655-661.
35. Hutchinson S. J., Taylor A., Goldberg D. J., Gruer L. Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990-1994: implications for control and prevention of blood-borne viruses. Addiction 2000; 95: 931-940.
36. Trimbos-instituut. Figure 4.9. In: National Drug Monitor 2007 Year Report [in Dutch]; 2008. p. 109. ISBN 978-90-5253-6149.
37. Genberg B. L., Gange S. J., Go V. F., Celentano D. D., Kirk G. D., Mehta S. H. Trajectories of injection drug use over 20 years (1988-2008) in Baltimore, Maryland. Am J Epidemiol 2011; 173: 829-836.
38. van Ameijden E. J., Langendam M. W., Coutinho R. A. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. Addict Behav 1999; 24: 559-563.
39. Deuffic-Burban S., Wong J. B., Valleron A. J., Costagliola D., Delfraissy J. F., Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40: 319-326.
40. Vickerman P. P., Platt L. L., Hawkes S. Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. Sex Transm Infect 2009; 85: ii23-30.
41. Grady B, van den Berg C, van der Helm J, Schinkel J, Coutinho R, Krol A etal. No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. Clin Gastroenterol Hepatol 2011; 9: 786-792.
42. Vlahov D., Junge B. The role of needle exchange programs in HIV prevention. Public Health Rep 1998; 113: 75-80.
43. Witteveen E., Van Ameijden E. J., Schippers G. M. Motives for and against injecting drug use among young adults in Amsterdam: qualitative findings and considerations for disease prevention. Subst Use Misuse 2006; 41: 1001-1016.